| You are here: Home: BCU 7|2003: Howard
A Burris III, MD: Select publications
Select publications
Publications discussed by Dr Burris
Chlebowski RT et al. American Society of
Clinical Oncology technology assessment of pharmacologic interventions
for breast cancer risk reduction including tamoxifen, raloxifene,
and aromatase inhibition. J Clin Oncol 2002;20(15):3328-43. Abstract
Loesch D et al. Phase II multicenter trial
of a weekly paclitaxel and carboplatin regimen in patients with
advanced breast cancer. J Clin Oncol 2002;20(18):3857-64. Abstract
Pegram MD et al. Phase II study of receptor-enhanced
chemosensitivity using recombinant humanized anti-p185HER2/neu
monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing
metastatic breast cancer refractory to chemotherapy treatment.
J Clin Oncol 1998;16(8):2659-71. Abstract
Perez EA et al. A phase II study of paclitaxel
plus carboplatin as first-line chemotherapy for women with metastatic
breast carcinoma. Cancer 2001;88(1):124-31. Abstract
Robert N et al. Phase III comparative study
of trastuzumab and paclitaxel with and without carboplatin in
patients with HER-2/neu positive advanced breast cancer. Breast
Cancer Res Treat 2002: Abstract 35.
Rowland KM et al. NCCTG 98-32-52: Randomized
phase II trial of weekly versus every 3-week administration of
paclitaxel, carboplatin and trastuzumab in women with HER2 positive
metastatic breast cancer (MBC). Proc ASCO 2003:Abstract 31.
Siena S et al. Multicenter phase II study
of temozolomide therapy for brain metastasis in patients with
malignant melanoma, breast cancer, and non-small cell lung cancer. Proc ASCO 2003:Abstract
407.
Sledge GW et al. Phase III trial of doxorubicin,
paclitaxel, and the combination of doxorubicin and paclitaxel
as front-line chemotherapy for metastatic breast cancer: An Intergroup
trial (E1193). J Clin
Oncol 2003;21(4):588-92. Abstract
Theodoulou M et al. [427] Cardiac safety
and efficacy of TLC D99 (D, MyocetT) and Herceptin (H) in advanced breast cancer (ABC). Breast Cancer Res Treat 2002:Abstract 427.
Winer EP et al. American Society of Clinical
Oncology technology assessment on the use of aromatase inhibitors
as adjuvant therapy for women with hormone receptor-positive
breast cancer: Status report 2002. J Clin Oncol 2002;20(15):3317-27. Abstract
Yardley DA et al. Final results of the Minnie
Pearl Cancer Research Network first-line trial of weekly paclitaxel/carboplatin/trastuzumab
in metastatic breast cancer. Breast Cancer Res Treat 2002:Abstract
439.
Yardley DA et al. Preserved chemosensitivity
to weekly paclitaxel and carboplatin in HER2+ patients irrespective
of responses to first-line intensified induction Herceptin single
agent therapy. Proc ASCO 2003:Abstract 127.
Trastuzumab/chemotherapy combinations in the treatment of metastatic
breast cancer
Bell R. What can we learn from Herceptin
trials in metastatic breast cancer? Oncology2002;63 Suppl 1:39-46. Abstract
Burstein HJ et al. Trastuzumab and vinorelbine
as first-line therapy for HER2-overexpressing metastatic breast
cancer: multicenter phase II trial with clinical outcomes, analysis
of serum tumor markers as predictive factors, and cardiac surveillance
algorithm.J Clin
Oncol 2003;21(15):2889-95. Abstract
Gianni L. The future of targeted therapy:
Combining novel agents. Oncology 2002;63 Suppl 1:47-56. Abstract
Harries M, Smith I. The development and clinical
use of trastuzumab (Herceptin). Endocr Relat Cancer 2002;9(2):75-85. Abstract
Ligibel JA, Winer EP. Trastuzumab/chemotherapy
combinations in metastatic breast cancer. Semin Oncol
2002 Jun;29(3 Suppl 11):38-43. Abstract
Miles D et al. Combination versus sequential
single-agent therapy in metastatic breast cancer. Oncologist
2002;7 Suppl 6:13-9. Erratum in: Oncologist. 2003;8(1):127. Abstract
Montemurro F et al. Safety and activity of
docetaxel and trastuzumab in HER2 overexpressing metastatic breast
cancer: A pilot phase II study. Am J Clin Oncol2003;26(1):95-7. Abstract
Nabholtz JM et al. HER2-positive breast cancer:
Update on Breast Cancer International Research Group trials. Clin
Breast Cancer 2002;3 Suppl 2:S75-9. Abstract
O'shaughnessy J. Gemcitabine and trastuzumab
in metastatic breast cancer. Semin Oncol2003;30(2 Suppl 3):22-6. Abstract
Osoba D et al. Effects on quality of life
of combined trastuzumab and chemotherapy in women with metastatic
breast cancer. J Clin
Oncol 2002;20(14):3106-13. Abstract
|
